FDA Approves New Alzheimer's Drug Shown in Clinical Trials to Slow Cognitive Decline in Patients in the Early Stages of the Illness.

4 Things You Should Know About Infusion Therapy

This year has posed some new challenges in the medical industry with immunocompromised patients concerned about their health due to Covid-19. Independent infusion service providers empower these at-risk patients to administer their medication in the home setting or at an infusion center.

Read More »

Highlights of Prescribing Information

These highlights do not include all the information needed to use Octagam 10% safely and effectively. See full prescribing information for Octagam 10%.

ProDERM Study Protocol

Prospective, double-blind, randomized, placebocontrolled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)

ADMA Biologics

ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System